DOC, or 2,5-dimethoxy-4-chloroamphetamine, is a synthetic psychedelic amphetamine in the DOx family. It has a chlorine atom at the 4-position of the phenyl ring and methoxy groups at the 2- and 5-positions. DOC acts primarily through serotonin receptors and is known for a long duration of action. Clinical reports include severe agitation, hyperthermia, seizures, organ failure and fatal intoxication.
Chemistry and history
DOC is the alpha-methylated amphetamine counterpart of 2C-C. The additional alpha-methyl group distinguishes it from the corresponding phenethylamine and contributes to the long-lasting effects associated with the DOx family.
DOC has appeared in illicit products, including blotter paper and powders, and has sometimes been misrepresented as LSD. The World Health Organization reviewed DOC in 2019 and recommended international control because of its hallucinogenic effects, lack of recognised therapeutic use and reports of serious intoxication (WHO critical review of DOC, 2019).
Pharmacology
DOC is a serotonergic hallucinogen whose effects are mediated predominantly through serotonin receptors, particularly 5-HT2A. The WHO review describes its actions as comparable to other hallucinogenic amphetamines, including DOB, DOM and DOI. Animal drug-discrimination studies also found effects similar to LSD and DMT rather than to conventional stimulants.
Its long duration is a recognised feature of the compound. The WHO review notes that human hallucinatory effects have been reported to persist for many hours, sometimes extending across much of a day.
Subjective effects
The PsychonautWiki profile of DOC describes a psychedelic experience with pronounced visual and cognitive effects. User accounts vary, but the clinical literature confirms that severe agitation and autonomic disturbance can occur.
Visual and cognitive effects
Reported effects include geometric visual patterns, changes in colour and depth perception, altered time perception and intensified thought. Euphoria and stimulation may occur, while anxiety, confusion, agitation and hallucinations are also described.
Physical effects
Clinical reports include tachycardia, hypertension, hyperthermia, sweating, tremor and seizures. Severe poisoning may progress to rhabdomyolysis, metabolic disturbance, renal injury and multiorgan failure.
Clinical toxicity
A 2017 report described five non-fatal cases of analytically confirmed DOC exposure in young adults. Severe presentations included agitation, hallucinations and autonomic symptoms, with patients requiring hospital treatment (DOC: clinical and analytical documentation of five non-fatal exposures, 2017).
A 2014 forensic report described a fatal intoxication in which DOC was the only drug of abuse identified in blood and urine, with caffeine also detected. The authors considered DOC the cause of death (Barnett and colleagues, 2014).
A later French case report described another fatal intoxication involving DOC alongside cannabis and evidence of previous alcohol consumption. The authors noted that low concentrations of a new psychoactive substance do not necessarily exclude a contribution to a fatal outcome, particularly in complex exposure histories (Lelievre and colleagues, 2022).
Toxicity and research limitations
The WHO review records both non-fatal and fatal intoxications and recommends international control. Severe cases have involved seizures, hyperthermia, agitation and organ injury. The available reports do not establish a reliable blood concentration threshold that predicts toxicity, and product misidentification can complicate clinical interpretation.
No controlled human study has established the long-term effects or dependence potential of DOC. Its serotonergic psychedelic action and ability to cause severe acute intoxication are better established.
Related compounds
DOC is related to DOB, DOI and DOM, which are members of the same psychedelic amphetamine family. It is the amphetamine counterpart of 2C-C.
Reviews
There are no reviews yet.